For anyone in Ellon searching for CJC-1295, the foundational reality is that this compound is available only through an online research supply market. What this means for Ellon researchers is that physical proximity is irrelevant compared to your ability to evaluate vendor quality — and those verification methods are accessible to anyone. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety screening. This guide gives Ellon researchers the practical tools to verify sourcing options methodically and source verified-quality CJC-1295 with confidence.
CJC-1295 Mechanisms Explained
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Ellon comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
Before evaluating any specific vendor, establish a quality benchmark — so you can identify whether a supplier meets the standard. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger severe inflammatory responses even at very low concentrations. For Ellon researchers evaluating unfamiliar vendors: a test quantity before committing to research volumes before scaling up your order is what experienced peptide researchers consistently do. The lyophilised (freeze-dried) form of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Ellon
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means safety data comes from animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Temperature excursions — even temporary temperature deviation — can compromise product integrity without any obvious sign; always use only material shipped with appropriate cold protection. Endotoxin testing in the CJC-1295 COA is absolutely required — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at minute levels, and no discount compensates for this missing data. Researchers using CJC-1295 alongside other research compounds should check the research literature for any reported interactions before beginning combination research.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
